Share
Therapies that can extend the life of cancer patients often have a negative impact on the skeleton, especially in those being treated for hormone-sensitive cancers. Evidence shows improvements in bone health when bisphosphonates and denosumab are administered. Patients diagnosed with cancer are living longer, with some unanticipated ramifications. According to Facts & Figures 2018, published...
Share
Artificial intelligence that can “read” electronic radiology reports and flag patients with broken bones who are at risk of osteoporosis outperformed the traditional manual method of health care professionals reading X-ray reports, a new study finds. The results were presented during a virtual news conference hosted by the Endocrine Society. The new search tool, called...
Share
New recommendations include romosozumab therapy for high risk patients The Endocrine Society today announced an update to its osteoporosis Clinical Practice Guideline to include recommendations for romosozumab, a new medication that was approved last year to treat postmenopausal women at high risk of fracture. The U.S. Food and Drug Administration approved romosozumab in April 2019,...
Share
Vitamin D enthusiasts have long promoted high doses to obtain hoped-for benefits, but clinical trials are not finding them. Clinical trials of high doses of vitamin D are not finding the benefits that some advocates had promoted and are even hinting at some adverse effects. “The enthusiasm for high-dose vitamin D has certainly outpaced the...
Share
A study from ENDO 2019 shows that postmenopausal women with diabetes can form new bone with walking after a meal either uphill or downhill, despite the poor bone quality associated with diabetes and a lack of the estrogen needed to prompt bone formation. Diabetes remains one of the biggest global health problems and is the...
Share
The Endocrine Society recently participated in a coalition of bone health experts, physicians, specialists, and patient advocacy groups to develop clinical care recommendations for the treatment of osteoporosis and resulting hip and spine fractures. The Secondary Fracture Prevention: Consensus Recommendations from a Multistakeholder Coalition was published online in the peer-reviewed Journal of Bone and Mineral...
Share
Women exposed to triclosan are more likely to develop osteoporosis, according to a study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Triclosan is an endocrine-disrupting chemical being widely used as an antibacterial in consumer goods and personal care products, including soaps, hand sanitizers, toothpaste, and mouthwash. A person can be exposed...
Share
The U.S. Food and Drug Administration has approved romosozumab-aqqg to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies. The drug will be marketed...
